Document series
Trial abstracts — page 10
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 10 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SUMMIT-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-4-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| SURMOUNT-4-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-4-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-OSA-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-OSA-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
| SURMOUNT-OSA-2-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-MASH-PKprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-MASH-RENAL-IMPprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ADHERENCEprogramme record | Survodutide | Phase 2 | Reported | Observational | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ELDERLYprogramme record | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-OBESITY-OLEprogramme record | Survodutide | Phase 2 | Reported | Single-arm open-label | — | 2024 | Very low |
| SYNERGY-NASH-BODY-COMPprogramme record | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SYNERGY-NASH-QOLprogramme record | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SYNERGY-NASH-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| CAGRI-SEMA-PH2-T2D-BODY-COMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-QOLprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-CNprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-JPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY-QOLprogramme record | Danuglipron | Phase 2b | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY-REGIONAL-CNprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY-REGIONAL-JPprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-BODY-COMPprogramme record | Danuglipron | Phase 2b | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-REGIONAL-CNprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
page 10 of 30